

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/698,121	10/30/2000	Jerome Aucouturier	58771.000012 5877	
21967 HUNTON & V	7590 08/09/2007 VILLIAMS LLP		EXAMINER	
INTELLECTUAL PROPERTY DEPARTMENT 1900 K STREET, N.W. SUITE 1200 WASHINGTON, DC 20006-1109			EWOLDT, GERALD R	
			ART UNIT	PAPER NUMBER
			1644	
			·	
			MAIL DATE	DELIVERY MODE
			08/09/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	09/698,121	AUCOUTURIER ET AL.			
Office Action Summary	Examiner	Art Unit			
	G. R. Ewoldt, Ph.D.	1644			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 16 Ag This action is FINAL . 2b) ☑ This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final.				
Disposition of Claims					
4) Claim(s) 19,20,30,31 and 33 is/are pending in the 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 19,20,30,31 and 33 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers	vn from consideration.				
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correction.	epted or b) objected to by the addrawing(s) be held in abeyance. See	∋ 37 CFR 1.85(a).			
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Po 6) Other:	ite			

Application/Control Number: 09/698,121

Art Unit: 1644

DETAILED ACTION

1. In view of the Appeal Brief filed on 4/16/07, PROSECUTION IS HEREBY REOPENED. New grounds of rejection are set forth below.

To avoid abandonment of the application, appellant must exercise one of the following two options:

(a) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR 1.113 (if this Office action is final); or,

Page 2

(b) request reinstatement of the appeal.

If reinstatement of the appeal is requested, such request must be accompanied by a supplemental appeal brief, but no new amendments, affidavits (37 CFR 1.130, 1.131 or 1.132) or other evidence are permitted. See 37 CFR 1.193(b)(2).

- 2. Claims 19, 20, 30, 31, and 33 are pending and being acted upon.
- 3. Upon reconsideration, the previous rejection of the claims under 35 U.S.C. 102(e) has been withdraw. In particular, the reference does not teach the elected species of adjuvant (surfactant or mixture of surfactants), composition H (Mannitan oleate (8 EOs)). As set forth by Applicant in the remarks of 3/13/02, the elected species comprises mannitan oleate with an ethoxylation indice of 8 ethoxylation units. Given that the elected species of adjuvant is free of the art, the search has been extended to include additional adjuvants.
- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 19, 20, 30, 31, and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 6,274,149.

Application/Control Number: 09/698,121

Art Unit: 1644

The '149 patent teaches a method providing an adjuvant effect to a vaccine comprising at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence, comprising combining said antigen or in vivo generator with a surfactant or with a mixture of surfactants, said surfactant or mixture of surfactants having an overall HLB number of between 5 and 15, wherein said vaccine is suitable for application mucosally, orally, nasally, rectally or vaginally. (see particularly, column 4, sorbitan and cyclic mannitan, and Table 1, MONTANIDE). The reference further teaches that the composition may be polyethoxylated, modified with ethylene oxide, or ethoxylated (column 4, lines 25-55). Given the wide range of EOs recited in the claims, 1-60, (Claim 19), and 5-15 (Claim 33), the choice of EOs comprises mere routine optimization of the adjuvant. Said routine optimization would have fallen well within the purview of the ordinarily skilled artisan at the time of the invention. Also note that the minimization of the number of EOs would simplify the production of the adjuvant thus the choice of fewer EOs would be the most obvious variation of the polyethoxylated adjuvant.

Page 3

6. No claim is allowed.

- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.
- 8. Please Note: Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

Art Unit: 1644

G.R. Ewoldt, Ph.D. Primary Examiner

Technology Center 1600

CHRISTINA CHAN

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600